|
Compound class:
Antibody
Comment: IGN523 is a humanized anti-CD98 (SLC3A2) monoclonal antibody being investigated as a potential therapy for acute myeloid leukemia (AML) [1-2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Hayes GM, Chinn L, Cantor JM, Cairns B, Levashova Z, Tran H, Velilla T, Duey D, Lippincott J, Zachwieja J et al.. (2015)
Antitumor activity of an anti-CD98 antibody. Int J Cancer, 137 (3): 710-20. [PMID:25556716] |
|
2. Lippincott J, H van der Horst E, Zachwieja J, Tran H. (2013)
Anti-cd98 antibodies and methods of use thereof. Patent number: WO2013078377 A1. Assignee: Igenica, Inc.. Priority date: 23/11/2011. Publication date: 30/05/2013. |
